Mitragynine Reduced Morphine-induced Conditioned Place Preference and Withdrawal in Rodents

Rittinarong Meepong, Thongchai Sooksawate

Abstract


Introduction: Kratom (Mitragyna speciosa Korth) has been long used in folklore medicine in Southeast Asian countries for its analgesic effects and the treatment of opioid withdrawal.  Mitragynine is a major alkaloid found in the leaves of kratom plant that is responsible for most of the kratom pharmacological effects.  It exerts its effects via activation of opioid receptors and other receptors in the central nervous system.  This study aimed to provide evaluation of abuse liability and potential of mitragynine in the treatment for opioid addictions.  Material and methods: Abuse liability of mitragynine was evaluated using drug discrimination and conditioned place preference models in rats and naloxone precipitated withdrawal model in mice.  The effects of mitragynine on acquisition and expression of morphine conditioned place preference were performed in rats.  Naloxone precipitated withdrawal was performed in mice treated with morphine.  Results and conclusions: Mitragynine fully substituted methamphetamine in drug discrimination model at 10 mg/kg.  It also induced conditioned place preference at doses of 30 and 60 mg/kg.  Acute withdrawal symptoms precipitated by naloxone by means of repeated jumping was significant in 60 mg/kg mitragynine treated group.  Straub tail reaction was observable in dose dependent from 10 mg/kg mitragynine.  In chronic withdrawal, repeated jumping behaviour of mitragynine was significant at 30 mg/kg.  Straub tail reaction was found in both 10 and 30 mg/kg mitragynine treated group.  Mitragynine attenuated acquisition and expression of morphine conditioned place preference in dose dependent manner from 10 to 30 mg/kg.  When given with morphine, 10 mg/kg mitragynine could reduce jumping behaviour to the same level as chronic treatment of 10 mg/kg mitragynine alone and 30 mg/kg mitragynine could reduce Straub tail reaction.  This study indicates that mitragynine had low abuse liability and could attenuate the acquisition and expression of morphine-induced conditioned place preference and precipitated withdrawal symptoms.  These results support the use of kratom in traditional medicine and self-medication for opioid addiction and withdrawal.

Full Text:

21-29;PDF

References


United Nations Office for Drug Control and Crime: World Drug Report 2017: United Nations publication; 2017.

Dematteis M, Auriacombe M, D'Agnone O, et al: Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother 2017; 18(18):1987-1999.

Suwanlert S: A study of kratom eaters in Thailand. Bull Narc 1975; 27(3):21-27.

Chan KB, Pakiam C, Rahim RA: Psychoactive plant abuse: the identification of mitragynine in ketum and in ketum preparations. Bull Narc 2005; 57(1-2):249-256.

Thongpradichote S, Matsumoto K, Tohda M, et al: Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. Life Sci 1998; 62(16):1371-1378.

Rätsch C: Mitragyna speciosa. In: The encyclopedia of psychoactive plants : ethnopharmacology and its applications. 1st U.S. edn. Rochester, Vt.: Park Street Press; 2005.

Beckett AH, Shellard EJ, Phillipson JD, et al: Alkaloids from Mitragyna speciosa (Korth.). J Pharm Pharmacol 1965; 17(11):753-755.

Grundmann O: Patterns of Kratom use and health impact in the US—Results from an online survey. Drug and Alcohol Dependence 2017; 176:63-70.

Cinosi E, Martinotti G, Simonato P, et al: Following “the roots” of kratom (Mitragyna speciosa): The evolution of an enhancer from a traditional use to increase work and productivity in southeast asia to a recreational psychoactive drug in western countries. BioMed Research International 2015; 2015:1-11.

Prozialeck WC, Jivan JK, Andurkar SV: Pharmacology of kratom: An emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc 2012; 112(12):792-799.

Arndt T, Claussen U, Güssregen B, et al: Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer. Forensic Science International 2011; 208(1-3):47-52.

Chittrakarn S, Penjamras P, Keawpradub N: Quantitative analysis of mitragynine, codeine, caffeine, chlorpheniramine and phenylephrine in a kratom (Mitragyna speciosa Korth.) cocktail using high-performance liquid chromatography. Forensic Science International 2012; 217(1-3):81-86.

Macko E, Weisbach JA, Douglas B: Some observations on the pharmacology of mitragynine. Arch Int Pharmacodyn Ther 1972; 198(1):145-161.

Takayama H: Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo) 2004; 52(8):916-928.

Brown PN, Lund JA, Murch SJ: A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna Korth: Implications for products sold as kratom. J Ethnopharmacol 2017; 202:302-325.

Taufik Hidayat M, Apryani E, Nabishah BM, et al: Determination of mitragynine bound opioid receptors. Adv Med Dent Sci 2010; 3(3):65-70.

Kruegel AC, Gassaway MM, Kapoor A, et al: Synthetic and receptor signaling explorations of the Mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc 2016; 138(21):6754-6764.

Shamima AR, Fakurazi S, Hidayat MT, et al: Antinociceptive action of isolated mitragynine from Mitragyna Speciosa through activation of opioid receptor system. Int J Mol Sci 2012; 13(9):11427-11442.

Matsumoto K, Mizowaki M, Suchitra T, et al: Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol 1996; 317(1):75-81.

Boyer EW, Babu KM, Adkins JE, et al: Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction 2008; 103(6):1048-1050.

Harun N, Hassan Z, Navaratnam V, et al: Discriminative stimulus properties of mitragynine (kratom) in rats. Psychopharmacology (Berl) 2015; 232(13):2227-2238.

Yusoff NHM, Mansor SM, Muller CP, et al: Opioid receptors mediate the acquisition, but not the expression of mitragynine-induced conditioned place preference in rats. Behav Brain Res 2017; 332:1-6.

Yusoff NHM, Mansor SM, Müller CP, et al: Baclofen blocks the acquisition and expression of mitragynine-induced conditioned place preference in rats. Behav Brain Res 2018; 345:65-71.

Ponglux D, Wongseripipatana S, Takayama H, et al: A New Indole Alkaloid, 7 α-Hydroxy-7H-mitragynine, fromMitragyna speciosain Thailand. Planta Medica 2007; 60(06):580-581.

Solinas M, Panlilio LV, Justinova Z, et al: Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc 2006; 1(3):1194-1206.

Dias C, Wang YT, Phillips AG: Facilitated extinction of morphine conditioned place preference with Tat-GluA23Y interference peptide. Behavioural Brain Research 2012; 233(2):389-397.

Mizoguchi H, Yamada K, Mizuno M, et al: Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. Mol Pharmacol 2004; 65(5):1293-1301.

Kest B, Palmese CA, Hopkins E, et al: Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 2002; 115(2):463-469.

Matsumoto K, Horie S, Takayama H, et al: Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci 2005; 78(1):2-7.

Yusoff NH, Suhaimi FW, Vadivelu RK, et al: Abuse potential and adverse cognitive effects of mitragynine (kratom). Addict Biol 2016; 21(1):98-110.

Shoaib M, Spanagel R, Stohr T, et al: Strain differences in the rewarding and dopamine-releasing effects of morphine in rats. Psychopharmacology (Berl) 1995; 117(2):240-247.

Bohn LM, Gainetdinov RR, Lin F-T, et al: μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408(6813):720-723.

Bilbey DL, Salem H, Grossman MH: The anatomical basis of the Straub phenomenon. Br J Pharmacol Chemother 1960; 15(4):540-543.

Nath C, Gupta MB, Patnaik GK, et al: Morphine-induced Straub tail response: mediated by central mu2-opioid receptor. Eur J Pharmacol 1994; 263(1-2):203-205.

Zarrindast MR, Alaei-Nia K, Shafizadeh M: On the mechanism of tolerance to morphine-induced Straub tail reaction in mice. Pharmacol Biochem Behav 2001; 69(3-4):419-424.

Stolt A-C, Schröder H, Neurath H, et al: Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract. Psychopharmacology (Berl) 2013; 231(1):13-25.

Carroll FI, Carlezon WA: Development of κ Opioid Receptor Antagonists. Journal of Medicinal Chemistry 2013; 56(6):2178-2195.

Helal MA, Habib ES, Chittiboyina AG: Selective kappa opioid antagonists for treatment of addiction, are we there yet? Eur J Med Chem 2017; 141:632-647.

Halpenny GM: Mitragyna speciosa: Balancing potential medical benefits and abuse. ACS Med Chem Lett 2017; 8(9):897-899.

Idayu NF, Hidayat MT, Moklas MA, et al: Antidepressant-like effect of mitragynine isolated from Mitragyna speciosa Korth in mice model of depression. Phytomedicine 2011; 18(5):402-407.

Whitfield TW, Jr., Schlosburg JE, Wee S, et al: Kappa opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J Neurosci 2015; 35(10):4296-4305.

Matsumoto K, Yamamoto LT, Watanabe K, et al: Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens. Life Sci 2005; 78(2):187-194.

Nakagawa T, Nagayasu K, Nishitani N, et al: Yokukansan inhibits morphine tolerance and physical dependence in mice: The role of α2A-adrenoceptor. Neuroscience 2012; 227:336-349.

Barrios M, Baeyens JM: Differential effects of L-type calcium channel blockers and stimulants on naloxone-precipitated withdrawal in mice acutely dependent on morphine. Psychopharmacology 1991; 104(3):397-403.

Seth V, Upadhyaya P, Moghe V, et al: Role of calcium in morphine dependence and naloxone-precipitated withdrawal in mice. J Exp Pharmacol 2011; 3:7-12.

Vitcheva V, Mitcheva M: Effects of nifedipine on behavioral and biochemical parameters in rats after multiple morphine administration. Methods Find Exp Clin Pharmacol 2004; 26(8):631-634.

Singh D, Narayanan S, Vicknasingam B: Traditional and non-traditional uses of mitragynine (kratom): A survey of the literature. Brain Res Bull 2016; 126:41-46.

Singh D, Muller CP, Vicknasingam BK: Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend 2014; 139:132-137.

Mackay L, Abrahams R: Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Physician 2018; 64(2):121-122.

Virk MS, Arttamangkul S, Birdsong WT, et al: Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci 2009; 29(22):7341-7348.

Dahan A: Potent opioid analgesia without respiratory depression. Anesthesiology 2016; 125(5):841-843.

Soyka M: Treatment of opioid dependence with buprenorphine: current update. Dialogues Clin Neurosci 2017; 19(3):299-308.

Vicknasingam B, Narayanan S, Beng GT, et al: The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy 2010; 21(4):283-288.


Refbacks

  • There are currently no refbacks.